Solutions

Online Inquiry

Your Name *

Phone Number *

E-mail Address *

Services Interested *

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Lymphocytic Choriomeningitis

Lymphocytic choriomeningitis (LCM) is an arenavirus that poses a significant threat to both immunocompetent and immunocompromised individuals. At our company, we provide comprehensive development services for vaccines and therapeutics targeting LCM.

Introduction to Lymphocytic Choriomeningitis

Lymphocytic choriomeningitis virus (LCMV) is a rodent-borne zoonotic virus belonging to the Arenaviridae family. It is primarily transmitted to humans through contact with infected rodents or their excretions. The virus is known to cause a spectrum of diseases, ranging from asymptomatic infections to severe neurological manifestations including aseptic meningitis and encephalitis. LCMV is of particular concern in immunocompromised individuals and pregnant women, where it can lead to severe outcomes such as congenital infection and fetal teratogenic effects.

Analysis of brain and eye pathology in lymphocytic choriomeningitis (LCM). Fig.1 Brain and ocular pathological features of lymphocytic choriomeningitis (LCM). (Tevaearai F., et al., 2022)

Vaccine Development for Lymphocytic Choriomeningitis

Recombinant LCMV Vaccines

These vaccines utilize genetic material from the virus to produce an immune response without causing disease. For instance, non-replicating recombinant LCMV (rLCMV) vectors have shown promise in preclinical models, inducing multifunctional cytotoxic CD8+ T-cells and memory T-cells, which are crucial for viral clearance.

Vector-Based Vaccines

Vector-based vaccines use a harmless virus to carry pieces of the LCMV into the body, triggering an immune response. Attenuated or inactivated versions of the virus can be used to create these vaccines. An example is the rLCMV vector expressing model antigens, which have been tested in immunocompromised mice, demonstrating safety and efficacy.

Therapeutics Development for Lymphocytic Choriomeningitis

Antiviral Therapies

The development of antiviral therapies for LCMV has been a focus due to the severe outcomes in certain populations. Ribavirin, an antiviral with broad-spectrum activity, has been used with limited success. In contrast, favipiravir, a pyrazinecarboxamide derivative, has shown potent antiviral activity in preclinical models, protecting against mortality and reducing viral loads dramatically.

Immunotherapies

Immunotherapies aim to bolster the immune system's natural defenses against LCMV. This includes the use of monoclonal antibodies that can neutralize the virus. For example, human monoclonal antibodies specific for Lassa virus glycoproteins have shown cross-reactivity with LCMV in vitro, suggesting potential therapeutic applications.

Our Services

With a seasoned research team well-versed in infectious diseases and equipped with cutting-edge technology platforms, our company is well-positioned to offer LCM vaccine and therapy development services with confidence. Tailoring personalized solutions and analytical processes to meet your unique scientific research requirements, we ensure real-time project tracking to expedite your scientific breakthroughs. Our services include:

Vaccine Development: We specialize in the formulation and testing of various vaccine types, including live-attenuated, inactivated, subunit, and genetic vaccines.
Antiviral Drug Discovery: Our team conducts research on potential antiviral compounds and therapeutic agents targeting LCMV.
Preclinical Research: We offer extensive preclinical research services, including efficacy and safety assessments, pharmacokinetics, and toxicology studies.

Diagnostics Development

Disease Models

Systemic LCMV Infection Models
Persistent LCMV Infection Models
RIP-LCMV Mouse Models
MBP-LCMV Mouse Models

Infection route: intraperitoneal, intravenous, subcutaneous, footpad, or intracranial injections

Vaccine Development

Therapeutic Development

The urgent need for effective vaccines and therapies against lymphocytic choriomeningitis is evident. Our company is committed to advancing the research and development of innovative solutions to combat this neglected viral infection. If you are interested in our services, please feel free to contact us.

References

Tevaearai, Fanny, Laureline Moser, and Léo Pomar. "Prenatal diagnosis of congenital lymphocytic choriomeningitis virus infection: a case report." Viruses 14.11 (2022): 2586.
Vilibic-Cavlek, Tatjana, et al. "Lymphocytic Choriomeningitis—emerging trends of a neglected Virus: A narrative review." Tropical medicine and infectious disease 6.2 (2021): 88.
Hickerson, Brady T., et al. "Effective treatment of experimental lymphocytic choriomeningitis virus infection: Consideration of favipiravir for use with infected organ transplant recipients." The Journal of Infectious Diseases 218.4 (2018): 522-527.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.